氟哌噻吨美利曲辛联合双歧三联活菌治疗难治性肠易激综合征临床疗效

The clinical efficacy of the treatment of flupentixol melitracen joint bifid triple viable on refractory irritable bowel syndrome

目的研究氟哌噻吨美利曲辛联合双歧三联活菌治疗难治性肠易激综合征(IBS)的临床疗效。方法选取82例难治性IBS患者分为观察组和对照组,每组41例。对照组给予双歧三联活菌胶囊治疗,观察组在双歧三联活菌胶囊治疗基础上给予氟哌噻吨美利曲辛片,疗程12周。比较两组患者临床总有效率和单项症状改善情况。结果观察组的临床总有效率为92.68%,明显高于对照组的65.85%(χ2=8.979,P<0.01);且观察组治疗后各项临床症状总有效率明显高于对照组,差异具有高度统计学意义(P<0.01)。结论双歧三联活菌胶囊联合氟哌噻吨美利曲辛片治疗难治性IBS临床疗效显著,可有效缓解患者各项临床症状,减轻痛苦,提高患者生活质量,可在临床上推广应用。

Objective To investigate the clinical efficacy of the treatment of flupentixol melitracen joint bifid triple vi- able on refractory irritable bowel syndrome（IBS）. Methods A total of 82 patients with refractory IBS patients were di- vided into observation group and the control group, 41 cases in each group. The control group was treated by bifid triple viable capsule, while the observation group was treated by give flupentixol melitracen joint bifid triple viable. The clinical efficiency and individual improvement of symptoms were compared between the two groups. Results The clinical total effective rate of the observation group was 92.68%, which was significantly higher than that of the control 65.85% （~2 = 8.979, P 〈 0.01 ）. Each clinical symptom in the observation group after treatment was always signifi- cantly higher than the control group＇s. Conclusion Bifid triple viable capsule combined with flupentixol melitracen can effectively alleviate the clinical symptoms and the suffering of patients, which can improve the quality of life of patients with refractory IBS and can be used widely in clinical application.